{"transactions":[{"id":2134433,"issuer":{"id":8618,"kind":"organization","name":"Odyssey Health, Inc."},"owners":[{"id":123004,"kind":"person","name":"VANLANDINGHAM JACOB PH.D","position":1,"cik":"0001794273","reported_name":"VANLANDINGHAM JACOB PH.D","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Related Party"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-19T21:27:09.000Z","date":"2022-10-14","kind":"grant","acquired":true,"shares":1000000,"price":0.318,"value":318000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting Schedule 250,000 upon signing; 250,000 upon an IND being approved by the FDA for Phase 2; 250,000 upon a listing on a national exchange (Nasdaq, NYSE); and 250,000 one year from Effective Date."}],"balance_after":2100000,"derivative":{"exercise_price":0.318,"expiration_date":"2032-10-13","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001683168-22-006969","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822006969/ownership.xml","form_type":"4"}},{"id":2232225,"issuer":{"id":8618,"kind":"organization","name":"Odyssey Health, Inc."},"owners":[{"id":123004,"kind":"person","name":"VANLANDINGHAM JACOB PH.D","position":1,"cik":"0001794273","reported_name":"VANLANDINGHAM JACOB PH.D","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"VP of Drug Development"}}],"security":"ODYY common stock $0.001 par value","published_at":"2022-06-14T16:10:46.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":1000000,"price":0.23,"value":230000.0,"ownership":{"direct":false,"nature":"By Prevacus, Inc."},"balance_after":9660000,"source":{"system":"sec-edgar","filing":"0001683168-22-004341","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822004341/ownership.xml","form_type":"4"}},{"id":2238671,"issuer":{"id":8618,"kind":"organization","name":"Odyssey Health, Inc."},"owners":[{"id":123004,"kind":"person","name":"VANLANDINGHAM JACOB PH.D","position":1,"cik":"0001794273","reported_name":"VANLANDINGHAM JACOB PH.D","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"VP of Drug Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-08T17:18:31.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":100000,"price":0.3,"value":30000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting Schedule: 50% vest on first dosed subject of Phase 2 Trial; 50% on last dosed subject of Phase 2 Trial."}],"balance_after":1100000,"derivative":{"exercise_price":0.3,"expiration_date":"2032-05-19","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001683168-22-004244","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822004244/ownership.xml","form_type":"4"}},{"id":2751825,"issuer":{"id":8618,"kind":"organization","name":"Odyssey Health, Inc."},"owners":[{"id":123004,"kind":"person","name":"VANLANDINGHAM JACOB PH.D","position":1,"cik":"0001794273","reported_name":"VANLANDINGHAM JACOB PH.D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-09T17:01:27.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":1000000,"price":1.18,"value":1180000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting schedule: 250,000 shares vest on signing of closing documents; 250,000 shares vest on Phase 1a first dosing of human; 250,000 shares vest on Phase 1b first dosing of human; and 250,000 shares vest upon Company being accepted on NASDAQ."}],"balance_after":1000000,"derivative":{"exercise_price":1.18,"expiration_date":"2024-03-01","underlying":"ODYY - Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001683168-21-001306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1626644/000168316821001306/ownership.xml","form_type":"4"}}]}